EW Edwards Lifesciences Corp
Price (delayed)
$72.05
Market cap
$42.36B
P/E Ratio
10.32
Dividend/share
N/A
EPS
$6.98
Enterprise value
$40.01B
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the SAPIEN transcatheter aortic heart valve made of
Highlights
The net income has soared by 198% YoY
The price to earnings (P/E) is 75% lower than the 5-year quarterly average of 41.5 and 58% lower than the last 4 quarters average of 24.8
EW's revenue is up by 9% year-on-year but it is down by 3% since the previous quarter
EW's gross profit is up by 7% year-on-year but it is down by 2.2% since the previous quarter
The debt has grown by 2.2% YoY
Key stats
What are the main financial stats of EW
Market
Valuations
Earnings
Shares outstanding
587.9M
Market cap
$42.36B
Enterprise value
$40.01B
Price to earnings (P/E)
10.32
Price to book (P/B)
4.25
Price to sales (P/S)
7.92
EV/EBIT
9.21
EV/EBITDA
8.83
EV/Sales
7.36
Revenue
$5.44B
Gross profit
$4.32B
Operating income
$1.38B
Net income
$4.17B
EBIT
$4.35B
EBITDA
$4.53B
Free cash flow
$289.9M
Per share
Balance sheet
Liquidity
EPS
$6.98
EPS diluted
$6.97
Free cash flow per share
$0.49
Book value per share
$16.95
Revenue per share
$9.1
TBVPS
$16.9
Total assets
$13.06B
Total liabilities
$2.99B
Debt
$700M
Equity
$10B
Working capital
$4.78B
Debt to equity
0.07
Current ratio
4.18
Quick ratio
3.12
Net debt/EBITDA
-0.52
Margins
Efficiency
Dividend
EBITDA margin
83.3%
Gross margin
79.5%
Net margin
76.7%
Operating margin
25.3%
Return on assets
36.4%
Return on equity
49%
Return on invested capital
70.9%
Return on capital employed
37.6%
Return on sales
79.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EW stock price
How has the Edwards Lifesciences stock price performed over time
Intraday
0.25%
1 week
1.35%
1 month
0.6%
1 year
-23.6%
YTD
-2.67%
QTD
-0.59%
Financial performance
How have Edwards Lifesciences's revenue and profit performed over time
Revenue
$5.44B
Gross profit
$4.32B
Operating income
$1.38B
Net income
$4.17B
Gross margin
79.5%
Net margin
76.7%
The net income has soared by 198% YoY
The net margin has soared by 174% YoY and by 3.4% from the previous quarter
EW's revenue is up by 9% year-on-year but it is down by 3% since the previous quarter
EW's gross profit is up by 7% year-on-year but it is down by 2.2% since the previous quarter
Growth
What is Edwards Lifesciences's growth rate over time
Valuation
What is Edwards Lifesciences stock price valuation
P/E
10.32
P/B
4.25
P/S
7.92
EV/EBIT
9.21
EV/EBITDA
8.83
EV/Sales
7.36
The price to earnings (P/E) is 75% lower than the 5-year quarterly average of 41.5 and 58% lower than the last 4 quarters average of 24.8
The stock's price to book (P/B) is 55% less than its 5-year quarterly average of 9.4 and 29% less than its last 4 quarters average of 6.0
The equity has surged by 50% year-on-year and by 4.7% since the previous quarter
The P/S is 29% below the 5-year quarterly average of 11.1 and 12% below the last 4 quarters average of 9.0
EW's revenue is up by 9% year-on-year but it is down by 3% since the previous quarter
Efficiency
How efficient is Edwards Lifesciences business performance
The company's return on invested capital has surged by 162% YoY
The company's return on sales has surged by 154% YoY and by 3.4% QoQ
EW's return on assets has surged by 136% year-on-year but it is down by 8% since the previous quarter
Edwards Lifesciences's return on equity has surged by 124% YoY but it has decreased by 9% QoQ
Dividends
What is EW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EW.
Financial health
How did Edwards Lifesciences financials performed over time
EW's quick ratio has surged by 51% year-on-year and by 16% since the previous quarter
The total assets is up by 39% year-on-year
The debt is 93% less than the equity
The equity has surged by 50% year-on-year and by 4.7% since the previous quarter
The company's debt to equity fell by 30% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.